What is UNCY's current stock price?

UNCY (Unicycive Therapeutics, Inc.) is currently trading at $8.08 with a market cap of $173.7M.

What sector is Unicycive Therapeutics, Inc. in?

Unicycive Therapeutics, Inc. (UNCY) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

UNCY Unicycive Therapeutics, Inc.

Healthcare

$8.08+5.90%ClosedMarket Cap: $173.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

51.24

P/S

0.00

EV/EBITDA

-3.93

DCF Value

$0.18

FCF Yield

-16.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-131.2%

ROA

-62.0%

ROIC

-77.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-12.8M	$—
Q4 null	$0.00	$-14.7M	$—
FY null	$0.00	$-26.6M	$—
Q3 null	$0.00	$-6.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

2 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

GuggenheimBuy

2026-05-13

BenchmarkSpeculative Buy

2026-04-06

GuggenheimBuy

2026-04-02

HC Wainwright & Co.Buy

2025-10-29

BenchmarkSpeculative Buy

2025-09-15

Trading Activity

Insider Trades

View All

Kenkare-Mitra Saradirector

SellThu May 21

Kenkare-Mitra Saradirector

SellThu May 21

Gupta Shalabh K.director, officer: CEO

SellThu May 21

Townsend Johnofficer: CFO

SellWed May 20

Jermasek Douglasofficer: EVP, Corporate Strategy

SellWed May 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.77

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Peers